NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Superluminal Medicines

Superluminal Medicines

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://www.superluminalrx.com/

Last Round

Strategic

Aug 14, 2025

Total Funding Raised

$153M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Superluminal Medicines is a biotechnology company that leverages generative biology, machine learning, and structural biology to accelerate the discovery and development of small molecule therapeutics.

Sector

Healthcare & Life Sciences

Verticals

Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

AI drug discoverysmall molecule designbiotech partnershipGPCR drug discoverycomputational drug designgenerative chemistrycardiometabolic therapeuticsobesity drug developmentin-silico ADMETADMETstructural biologydrug discovery platformAI-first biotechpharma R&Ddrug discovery AI

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Superluminal Medicines Comparables

Compare Superluminal Medicines with similar companies based on industry and business-model similarity.

Superluminal Medicines comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Genesis Molecular AI
83%
Fathom Therapeutics
83%
Terray
81%

Superluminal Medicines Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
StrategicAug 14, 2025
Series ASep 9, 2024
SeedAug 28, 2023

Superluminal Medicines Investors

Notable investors and investment history

Superluminal Medicines investors
InvestorRounds
RA Capital ManagementSeed, Series A
GaingelsSeed, Series A
Catalio Capital ManagementSeries A
NVenturesSeries A
CooleySeries A
Insight PartnersSeed, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Grew 28% QoQ, from 40 to 51 employees.

  • Aug 14, 2025

    Eli Lilly and Company led the strategic round.

Superluminal Medicines Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Superluminal Medicines Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Superluminal Medicines's valuation, stock price, and market status.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range51
Year Founded2023
Last FundingAug 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.